This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064173%3A_____%2F11%3A%230000290%21RIV12-MZ0-00064173/
n10http://linked.opendata.cz/resource/domain/vavai/subjekt/
n6http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064173%3A_____%2F11%3A%230000290%21RIV12-MZ0-00064173
rdf:type
n6:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.1007/s00403-010-1080-1
dcterms:description
Patients with moderate to severe psoriasis are undertreated. To solve this persistent problem, the consensus programme was performed to define goals for treatment of plaque psoriasis with systemic therapy and to improve patient care. An expert consensus meeting and a collaborative Delphi procedure were carried out. Nineteen dermatologists from different European countries met for a face-to-face discussion and defined items through a four-round Delphi process. Severity of plaque psoriasis was graded into mild and moderate to severe disease. Mild disease was defined as body surface area (BSA) 10 or PASI > 10) and DLQI > 10. Special clinical situations may change mild psoriasis to moderate to severe including involvement of visible areas or severe nail involvement. For systemic therapy of plaque psoriasis two treatment phases were defined: (1) induction phase as the treatment period until week 16; however, depending on the type of drug and dose regimen used, this phase may be extended until week 24 and (2) maintenance phase for all drugs was defined as the treatment period after the induction phase. For the definition of treatment goals in plaque psoriasis, the change of PASI from baseline until the time of evaluation (DeltaPASI) and the absolute DLQI were used. After induction and during maintenance therapy, treatment can be continued if reduction in PASI is >/=75%. The treatment regimen should be modified if improvement of PASI is <50%. In a situation where the therapeutic response improved >/=50% but <75%, as assessed by PASI, therapy should be modified if the DLQI is >5 but can be continued if the DLQI is Patients with moderate to severe psoriasis are undertreated. To solve this persistent problem, the consensus programme was performed to define goals for treatment of plaque psoriasis with systemic therapy and to improve patient care. An expert consensus meeting and a collaborative Delphi procedure were carried out. Nineteen dermatologists from different European countries met for a face-to-face discussion and defined items through a four-round Delphi process. Severity of plaque psoriasis was graded into mild and moderate to severe disease. Mild disease was defined as body surface area (BSA) 10 or PASI > 10) and DLQI > 10. Special clinical situations may change mild psoriasis to moderate to severe including involvement of visible areas or severe nail involvement. For systemic therapy of plaque psoriasis two treatment phases were defined: (1) induction phase as the treatment period until week 16; however, depending on the type of drug and dose regimen used, this phase may be extended until week 24 and (2) maintenance phase for all drugs was defined as the treatment period after the induction phase. For the definition of treatment goals in plaque psoriasis, the change of PASI from baseline until the time of evaluation (DeltaPASI) and the absolute DLQI were used. After induction and during maintenance therapy, treatment can be continued if reduction in PASI is >/=75%. The treatment regimen should be modified if improvement of PASI is <50%. In a situation where the therapeutic response improved >/=50% but <75%, as assessed by PASI, therapy should be modified if the DLQI is >5 but can be continued if the DLQI is Patients with moderate to severe psoriasis are undertreated. To solve this persistent problem, the consensus programme was performed to define goals for treatment of plaque psoriasis with systemic therapy and to improve patient care. An expert consensus meeting and a collaborative Delphi procedure were carried out. Nineteen dermatologists from different European countries met for a face-to-face discussion and defined items through a four-round Delphi process. Severity of plaque psoriasis was graded into mild and moderate to severe disease. Mild disease was defined as body surface area (BSA) 10 or PASI > 10) and DLQI > 10. Special clinical situations may change mild psoriasis to moderate to severe including involvement of visible areas or severe nail involvement. For systemic therapy of plaque psoriasis two treatment phases were defined: (1) induction phase as the treatment period until week 16; however, depending on the type of drug and dose regimen used, this phase may be extended until week 24 and (2) maintenance phase for all drugs was defined as the treatment period after the induction phase. For the definition of treatment goals in plaque psoriasis, the change of PASI from baseline until the time of evaluation (DeltaPASI) and the absolute DLQI were used. After induction and during maintenance therapy, treatment can be continued if reduction in PASI is >/=75%. The treatment regimen should be modified if improvement of PASI is <50%. In a situation where the therapeutic response improved >/=50% but <75%, as assessed by PASI, therapy should be modified if the DLQI is >5 but can be continued if the DLQI is
dcterms:title
Definition of treatment goals for moderate to severe psoriasis: a European consensus Definition of treatment goals for moderate to severe psoriasis: a European consensus Definition of treatment goals for moderate to severe psoriasis: a European consensus
skos:prefLabel
Definition of treatment goals for moderate to severe psoriasis: a European consensus Definition of treatment goals for moderate to severe psoriasis: a European consensus Definition of treatment goals for moderate to severe psoriasis: a European consensus
skos:notation
RIV/00064173:_____/11:#0000290!RIV12-MZ0-00064173
n6:predkladatel
n10:ico%3A00064173
n3:aktivita
n4:N
n3:aktivity
N
n3:cisloPeriodika
1
n3:dodaniDat
n7:2012
n3:domaciTvurceVysledku
n15:6628885
n3:druhVysledku
n18:J
n3:duvernostUdaju
n16:S
n3:entitaPredkladatele
n11:predkladatel
n3:idSjednocenehoVysledku
193119
n3:idVysledku
RIV/00064173:_____/11:#0000290
n3:jazykVysledku
n12:cze
n3:klicovaSlova
Psoriasis, Treatment goals, Severity, Patient care, Consensus
n3:klicoveSlovo
n9:Severity n9:Psoriasis n9:Patient%20care n9:Consensus n9:Treatment%20goals
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[60D30D8D2CCB]
n3:nazevZdroje
Archives of Dermatological Research
n3:obor
n17:FO
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
26
n3:rokUplatneniVysledku
n7:2011
n3:svazekPeriodika
303
n3:tvurceVysledku
Iversen, L. Reich, A. Rantanen, T. Arenberger, P. Gisondi, P. Correia, O. Mrowietz, U. Yawalkar, N. Kragballe, K. Bylaite, M. Nijsten, T. Rosenbach, T. Volc-Platzer, B. Griffiths, CEM Talme, T. Antoniou, C. Reich, K. Kemeny, L. Spuls, P. Dauden, E. Segaert, S. Lahfa, M. Balieva, F. Franke, J. Nast, A. Smith, C.
s:issn
0340-3696
s:numberOfPages
10